Keywords: ملانوم متاستاتیک; allergic reaction; antitumor response; antitumor response toxic epidermal necrolysis; BRAF inhibitor; BRAF inhibitor Stevens-Johnson syndrome; BRAF inhibitor toxic epidermal necrolysis; coBRIM allergic reaction; coBRIM adverse effect; coBRIM hypersensitiv
مقالات ISI ملانوم متاستاتیک (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ملانوم متاستاتیک; Anti-CTLA4; anti-PD-1; BRAF inhibitor; effectiveness; metastatic melanoma; population-based study;
Keywords: ملانوم متاستاتیک; acral lentiginous melanoma; Asia; metastatic melanoma; nodal melanocytic nevi; sentinel lymph node biopsy; 5-year overall survival; ALM; acral lentiginous melanoma; CLND; completion regional lymph node dissection; EORTC; European Organization for Research
Keywords: ملانوم متاستاتیک; Radiotherapy; Metastatic melanoma; SBRT; Hypofractionation; Outcomes;
Keywords: ملانوم متاستاتیک; ICP; immune checkpoint; MM; metastatic melanoma; NPHT; nanoparticle-assisted hyperthermia; NIR; near-infrared; AMF; alternating magnetic field; PTT; photothermal therapy; MFH; magnetic field hyperthermia; RFH; radiofrequency hyperthermia; Nanoparticles; H
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Microtubule destabilizer; Polymer drug conjugate; Nanomedicine;
Keywords: ملانوم متاستاتیک; Access; Innovative medicines; Metastatic melanoma; Treatment; Immunooncology; Targeted therapy; Health expenditure per capita; Human development index;
Keywords: ملانوم متاستاتیک; B-Raf inhibitors; Mitogen-activated protein kinase inhibitor; Anti-Cytotoxic T-lymphocyte-associated protein 4; Anti-Programmed cell death-1; Metastatic melanoma; Cutaneous adverse event; Inhibidores de BRAF; Inhibidores de MEK; Anti-CTLA4; Anti-PD1; Mela
Keywords: ملانوم متاستاتیک; Cancer target; Nanomedicine; Metastatic melanoma; Immunoliposome; ICAM-1; Drug delivery;
Keywords: ملانوم متاستاتیک; B-Raf inhibitors; Mitogen-activated protein kinase inhibitor; Anti-Cytotoxic T-lymphocyte-associated protein 4; Anti-Programmed cell death-1; Metastatic melanoma; Cutaneous adverse event; Inhibidores de BRAF; Inhibidores de MEK; Anti-CTLA4; Anti-PD1; Mela
Keywords: ملانوم متاستاتیک; immune therapy; metastatic melanoma; targeted therapy; APC; antigen presenting cells; BRAF; v-RAF murine sarcoma viral oncogene; CRR; complete response rate; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; irAEs; immune related adverse events; KA;
Keywords: ملانوم متاستاتیک; Melanoma; Metastatic melanoma; Sentinel node biopsy; Intra-nodal naevi; Isolated tumour cells
Keywords: ملانوم متاستاتیک; Melanoma; progression; naevi; dysplastic naevi; radial growth phase; vertical growth phase; metastatic melanoma; genomics
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Biological therapy; Adjunctive morphological studies; Complications of treatment
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Treatment; Mandible
Keywords: ملانوم متاستاتیک; ABCDE criteria; age; dysplastic nevus syndrome; immunosuppression; melanoma; metastatic melanoma;
Keywords: ملانوم متاستاتیک; Immunotherapy; Antitumor immunity; Metastatic melanoma; Costimulatory blockade; Innate immunity; Adaptive immunity;
Keywords: ملانوم متاستاتیک; AurkA; aurora kinase A; MM; metastatic melanoma; IPA; Ingenuity Pathway Analysis; GSEA; Gene Set Enrichment Analysis; FDR; false discovery rate; Targeted therapy; Aurora kinase A in melanoma; Gene expression; Pathway analysis; Ran signaling;
Keywords: ملانوم متاستاتیک; curcumin; nanotechnology; muco adhesive; intestinal absorption; chitosan; drug delivery systems; in vitro models; B16F10 cells; metastatic melanoma; mouse model;
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Metastasectomy; Oligometastases; Stage IV melanoma; Surgery;
Keywords: ملانوم متاستاتیک; metastatic melanoma; rapid expansion; tumor-infiltrating lymphocytes; Wave bioreactor;
Keywords: ملانوم متاستاتیک; Oral medicine; temporomandibular joint disorders; pain; orofacial; neoplasms; metastatic melanoma; MRI; Magnetic resonance image/imaging; PET; Positron emission tomographic/tomography; TMD; Temporomandibular disorder; TMJ; Temporomandibular joint;
Keywords: ملانوم متاستاتیک; Metastases to bone; Metastatic carcinoma; Metastatic melanoma; Immunohistology; Gene chip analysis;
Keywords: ملانوم متاستاتیک; Neck; Axilla; Dissection; Lymphadenectomy; Skin cancer; Metastatic melanoma; Cervicoaxillary canal; Claviculectomy; Claviculotomy;
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Immunotherapy; CTLA-4; Blocking antibodies; Tremelimumab; Ipilimumab; Anti-PD1;
Keywords: ملانوم متاستاتیک; Urethral melanoma; Urethral duct invasion; Invasion of von Brunn nests; Metastatic melanoma; Extramammary Paget's disease
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Targeted Therapy; Immune-related adverse events; BRAF inhibitor melanoma;
L'immunohistochimie (clone VE1) est une méthode économique, spécifique et sensible pour détecter la présence d'une mutation BRAFV600E dans le mélanome
Keywords: ملانوم متاستاتیک; BRAF p.Val600Glu (V600E); Immunohistochimie; Mélanome métastatique; Thérapies ciblées; BRAF pVal600Glu (V600E); Immunohistochemistry; Metastatic melanoma; Targeted therapies;
Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Abscopal effect; Radiation therapy; Immunotherapy; NCDB;
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Keywords: ملانوم متاستاتیک; Metastatic melanoma; BRAF inhibitors; BRAFi; MEKi;
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma
Keywords: ملانوم متاستاتیک; Metastatic melanoma; PD-L1 expression; BRAF mutation; BRAF inhibitors; MEK inhibitors; Biomarker;
Original ResearchThe majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Immunotherapy; Phase III trials; Patient selection; Real-world patients;
ReviewThe mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition
Keywords: ملانوم متاستاتیک; Metastatic melanoma; MAP kinase pathway; BRAF mutation; PI3K pathway; Primary resistance to targeted therapy;
Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma
Keywords: ملانوم متاستاتیک; MM; metastatic melanoma; real-time PCR; real-time polymerase chain reaction; IHC; immunohistochemistry; FFPE; formaldehyde fixed-paraffin-embedded; BRAF mutation; Real-time PCR; Pyrosequencing; Immunohistochemistry;
MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition
Keywords: ملانوم متاستاتیک; Metastatic melanoma; MAP kinase pathway; BRAF mutation; Secondary and adaptive resistance; Immune effects of BRAF inhibition;
Original ResearchOpen-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
Keywords: ملانوم متاستاتیک; BRAFV600 mutation; Metastatic melanoma; Vemurafenib; Safety;
Original ResearchProgrammed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Nivolumab; Pembrolizumab; PD-1 inhibitor; Autoimmunity; Ipilimumab; Immune-related adverse events;
Original ResearchDutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands
Keywords: ملانوم متاستاتیک; Quality assurance; Metastatic melanoma; Checkpoint inhibitors; MAP kinase inhibitors; Population-based; Registry; Ipilimumab;
Attenuated in vitro effects of IFN-α, IL-2 and IL-12 on functional and receptor characteristics of peripheral blood lymphocytes in metastatic melanoma patients
Keywords: ملانوم متاستاتیک; NK; natural Killer; CTL; cytotoxic T lymphocytes; MM; metastatic melanoma; NKG2D; natural killer group 2 D; NCR; natural cytotoxicity receptor; KIR; killer cell immunoglobulin-like receptor; HLA; human leukocyte antigen; MICA/B; MHC-class-I-polypeptide-re
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
Keywords: ملانوم متاستاتیک; anti-programmed cell death-1; eczema; immune reaction; immunotherapy; lichenoid reaction; metastatic melanoma; vitiligo; AE; adverse event; BRAFI; BRAF inhibitor; FDA; Food and Drug Administration; PD; programmed cell death; SCC; squamous cell carcinoma;
CD271 Down-Regulation Promotes Melanoma Progression and Invasion in Three-Dimensional Models and in Zebrafish
Keywords: ملانوم متاستاتیک; 3D; three-dimensional; HIF-1α; hypoxia inducible factor-1α; MIC; melanoma-initiating cell; MM; metastatic melanoma; MTT; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PM; primary melanoma;
New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations
Keywords: ملانوم متاستاتیک; ATP; adenosine triphosphate; BRAF; serine/threonine-protein kinase B-Raf; cAMP; cyclic adenosine monophosphate; CDK4; cyclin-dependent kinases 4; CREB; cAMP response element binding protein; DMEM; Dulbecco's modified Eagle's medium; DMSO; dimethyl sulfoxi
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis
Keywords: ملانوم متاستاتیک; CTL; cytotoxic T lymphocyte; LN; lymph node; mLN; metastatic lymph node; MM; metastatic melanoma; NK; natural killer; OS; overall survival; PFS; progression-free survival; TIL; tumor-infiltrated lymphocyte;
Prognostic score for patients with advanced melanoma treated with ipilimumab
Keywords: ملانوم متاستاتیک; Metastatic Melanoma; Ipilimumab; Risk Factors; Prognostic Score;
Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma
Keywords: ملانوم متاستاتیک; immunohistochemistry; metastatic melanoma; molecular biology; NRAS; Q61R mutation; SP174 clone
Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
Keywords: ملانوم متاستاتیک; Vemurafenib; BRAF inhibitor; Metastatic melanoma;
Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Ipilimumab; Immunotherapy; Nomogram; Prognostic model;
Efficacy and safety of ipilimumab 3Â mg/kg in patients with pretreated, metastatic, mucosal melanoma
Keywords: ملانوم متاستاتیک; Efficacy; Expanded access programme; Ipilimumab; Metastatic melanoma; Mucosal; Safety;
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma
Keywords: ملانوم متاستاتیک; Metastatic melanoma; Phase II; Ramucirumab
AAV–sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo
Keywords: ملانوم متاستاتیک; BTLA; HSP70 vaccine; AAV; Immunotherapy; Metastatic melanoma